Results 221 to 230 of about 58,845 (265)
Modeling tumor dynamics and predicting response to therapies in a murine pancreatic cancer model. [PDF]
NPJ Syst Biol ApplVishwanath K +6 more
europepmc +1 more source
FGF12 induces aberrant mechanosignaling in aortic smooth muscle cells during thoracic aortic aneurysm formation in Marfan syndrome mice. [PDF]
Exp Mol MedKim KL +11 more
europepmc +1 more source
Adherence, Switches, and Drug Spending After Angiotensin Receptor Blocker Recalls and Shortages.
JAMA Health ForumCallaway Kim K +7 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs, 2003
Losartan is an orally active, selective, nonpeptide, angiotensin II AT(1) receptor antagonist. Losartan 50 or 100 mg/day was significantly more effective than placebo in reducing the incidence of a doubling of serum creatinine, end-stage renal disease (ESRD) or death (43.5% vs 47.1%, p = 0.02) in a pivotal, well designed trial (Reduction of Endpoints ...
Christopher I, Carswell, Karen L, Goa
+6 more sources
Losartan is an orally active, selective, nonpeptide, angiotensin II AT(1) receptor antagonist. Losartan 50 or 100 mg/day was significantly more effective than placebo in reducing the incidence of a doubling of serum creatinine, end-stage renal disease (ESRD) or death (43.5% vs 47.1%, p = 0.02) in a pivotal, well designed trial (Reduction of Endpoints ...
Christopher I, Carswell, Karen L, Goa
+6 more sources
Reactions Weekly, 2000
Abstract This chapter describes the evolution of the synthesis of the cardiovascular drug losartan potassium 1. This molecule, now largely in use as an antihypertensive agent, was the first approved drug of its class. The claims of the patents filed by DuPont/Merck’s researchers over the years determined the synthetic approaches that ...
Walter Cabri, Romano Di Fabio
openaire +2 more sources
Abstract This chapter describes the evolution of the synthesis of the cardiovascular drug losartan potassium 1. This molecule, now largely in use as an antihypertensive agent, was the first approved drug of its class. The claims of the patents filed by DuPont/Merck’s researchers over the years determined the synthetic approaches that ...
Walter Cabri, Romano Di Fabio
openaire +2 more sources